Peripheral Neuropathy Due to Chemotherapy Clinical Trial
Official title:
Evaluation of The Effect of N-AcetylCysteine in The Prevention of Paclitaxel-Induced Peripheral Neuropathy in Cancer Patients
The purpose of the study is to evaluate the effect of N-acetyl cysteine in combination with
paclitaxel on the clinical outcomes of patients with peripheral neuropathy,
paclitaxel-induced peripheral neuropathy affect quality of life in cancer patients.
new therapeutic approches such as the antioxidant N-acetyl cysteine, showed to has
neuroprotective effect, the aim of the study is to evaluate the effect of N-
acetylcysteine(NAC) administration in the prevention of paclitaxel-Induced peripheral
neuropathy.
Paclitaxel is a first-line chemotherapeutic treatment of solid tumors. Neuronal damage also
seems to have a major role in paclitaxel-induced neuropathic pain, paclitaxel contributes to
ROS formation (superoxide, hydroxyl radical, nitric oxide and hydrogen peroxide) in neuronal
mitochondria that are involved in nerve injury-induced.
N-acetylcysteine (NAC) is a cysteine pro-drug and glutathione (GSH) precursor which is a
protective agent and detoxifies and scavenges reactive oxygen species (ROS), which seems to
help normalize the oxidative status.
It has been reported that high dose of N-acetylcysteine shown to Prevent retrograde motor
neuron death after neonatal peripheral nerve injury and significantly increases motor neuron
survival, which may improve functional outcomes after obstetrical brachial plexus injury in
rats.
Also, it has been reported that NAC significantly inhibited CCI-induced microglia activation
but elicited no notable effects on astrocytes. These results demonstrate an effective and
safe approach that has been used clinically to alleviate neuropathic pain via the powerful
inhibition of the activation of MMPs in rats.
N-acetylcysteine has been shown to have neuroprotective effects against oxaliplatin-based
adjuvant chemotherapy in colon cancer patients with Oral administration of
N-acetylcysteine1,200 mg) was given one and a half hours before each oxaliplatin
administration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05875610 -
Preventive Approach Using Venlafaxine
|
Phase 4 | |
| Not yet recruiting |
NCT06313359 -
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
|
||
| Recruiting |
NCT03571334 -
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
|
Phase 2 | |
| Completed |
NCT04461977 -
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
|
N/A | |
| Recruiting |
NCT06135493 -
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
|
Phase 2 |